InvestSMART

Mayne Pharma Group Limited (ASX:MYX)

ALERT: Price-sensitive ASX Announcement for MYX
Current share price for MYX : $3.260 0.57 (21.19%)+
Announcement
Release
29 Apr 2026 9:33AM
Price at Release
$2.690
Full Release
download
Summary
Mayne Pharma Group Limited reported its unaudited 3Q FY26 results, highlighting a successful launch of DistributeRx, resulting in prescription volumes exceeding internal forecasts. The Women's Health segment showed strong growth, particularly with BIJUVA® and NEXTSTELLIS®. Despite a US tariff proclamation, the company saw a revenue increase to $85.2 million and a 57% improvement in underlying EBITDA. Adjusted operating cash flow surged by 90% due to effective working capital management. Mayne Pharma plans to focus on expanding its Women's Health and Dermatology segments, while exploring new opportunities post the Salisbury facility upgrade.
Key Points
  • Successful launch of DistributeRx with strong initial demand.
  • Growth in Women’s Health segment with BIJUVA® and NEXTSTELLIS®.
  • No material impact from US tariff proclamation.
  • Revenue of $85.2 million, a 1% increase from the previous year.
  • Underlying EBITDA improved by 57% to -$1.4 million.
  • Adjusted operating cash flow increased by 90% to $28.3 million.
  • Net cash flow of $19.3 million with cash reserves at $86.7 million.
  • BIJUVA® received FDA update removing certain warnings.
  • Continued focus on Women’s Health and Dermatology segments.
  • Exploration of new global partnerships after the Salisbury facility upgrade.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.